Dennis Slamon, M.D., Ph Flagyl Online .D., Wolfgang Eiermann, M.D., Nicholas Robert, M.D., Tadeusz Pienkowski, M.D., Miguel Martin, M.D., Michael Press, M.D., Ph.D., John Mackey, M.D., John Glaspy, M.D., Arlene Chan, M.D., Marek Pawlicki, M.D., Tamas Pinter, M.D., Vicente Valero, M.D., Mei-Ching Liu, M.D., Guido Sauter, M.D., Gunter von Minckwitz, M.D., Frances Visco, J.D., Valerie Bee, M.Sc., Marc Buyse, Sc.D., Belguendouz Bendahmane, M.D., Isabelle Tabah-Fisch, M.D., Mary-Ann Lindsay, Pharm.D., Alessandro Riva, M.D., and John Crown, M.D.
The first writer wrote the 1st draft of the manuscript, and all the authors provided remarks on subsequent drafts and made the decision to send the manuscript for publication. The trial process and statistical analysis program can be found at NEJM.org. The sponsors provided the medications for the scholarly study. Study Population The main inclusion criterion for the trial was an acute coronary syndrome within the prior 7 days, with symptoms of myocardial ischemia long lasting 10 minutes or more with the patient at rest plus either elevated levels of cardiac biomarkers or powerful ST-segment depression or elevation of 0.1 mV or more. Individuals who fulfilled this criterion were qualified to receive the analysis if their condition was clinically steady and they were receiving standard treatment after the acute coronary syndrome, including aspirin or aspirin plus any P2Y12-receptor antagonist.